Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06390956 · ClinicalTrials.gov registry record · Phase 2

Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)

A Phase 2 study of Marginal Zone Lymphoma, sponsored by University of Utah.

Recruiting
Registry status
Phase 2
Development phase
23
Enrollment target
2
Study locations

NCT06390956: Recruiting Phase 2 study of Marginal Zone Lymphoma, sponsored by University of Utah.

NCT06390956 is a Phase 2 study of Marginal Zone Lymphoma that is actively recruiting participants, run by University of Utah. The registered enrollment target is 23 participants, below the 102-participant average among 49 other Marginal Zone Lymphoma trials with a reported enrollment target (77% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06390956, a Phase 2 study of Marginal Zone Lymphoma, is actively recruiting participants, sponsored by University of Utah.

RECRUITING
Registry status
Phase 2
Development phase
23 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this clinical trial is to learn if the drugs Pirtobrutinib and Rituximab are effective for the treatment of newly diagnosed marginal zone lymphoma.

Primary Outcome

To assess the ORR in the study population at Cycle 7.

Conditions Studied

Marginal Zone Lymphoma

Interventions

  • DRUG Rituximab
  • DRUG Pirtobrutinib

Study Locations (2)

Missouri

  • Washington University - St Louis

Utah

  • Huntsman Cancer Institute at University of Utah - Salt Lake City

Trial Details

FieldValue
Enrollment Target 23 participants
Start Date 2025-02-20
Est. Completion 2032-12
Phase Phase 2
University of Utah

818 total trials

What NCT06390956 shows while recruiting

NCT06390956 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 102-participant average among 49 other Marginal Zone Lymphoma trials with a reported enrollment target (77% lower).

The record links to 1 condition, with Marginal Zone Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Rituximab is the first listed.

NCT06390956 reports a single indexed study location in Missouri, Utah.

Frequently Asked Questions

What is clinical trial NCT06390956 about?

NCT06390956 is a clinical study titled "Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)". The purpose of this clinical trial is to learn if the drugs Pirtobrutinib and Rituximab are effective for the treatment of newly diagnosed marginal zone lymphoma.

What is the current status of trial NCT06390956?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2025-02-20. Estimated completion is 2032-12.

What conditions does trial NCT06390956 study?

This clinical trial studies the following conditions: Marginal Zone Lymphoma.

What interventions are being tested in trial NCT06390956?

The interventions under investigation include: Rituximab (DRUG), Pirtobrutinib (DRUG).

Who is sponsoring clinical trial NCT06390956?

This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06390956 being conducted?

This trial has 2 study locations across Missouri, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Marginal Zone Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06390956's enrollment target sits among peer trials

23 43rd of 49 higher than 6 of 49 other Marginal Zone Lymphoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Marginal Zone Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03616041 · 23 participants

    Capsule Endoscopy for Severe Hematochezia

  • NCT04348747 · 23 participants · Phase 2

    Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer

  • NCT04587687 · 23 participants · Phase 2

    Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

  • NCT04715022 · 23 participants · Phase 1

    Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06390956

Source: ClinicalTrials.gov NCT06390956, the US trial registry maintained by the National Library of Medicine. NCT06390956 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.